China Grants Fujian Cosunter Pharma Breakthrough Designation for Hepatitis B Drug; Shares Slide 5%

MT NewswiresDec 16 14:53

Express News | Fujian Cosunter Pharmaceutical: The Innovative Drug Nai Ru Ke Wei GST-HG141 has been included in the list of breakthrough therapies for hepatitis B treatment.

BreakingsDec 15 16:30

Express News | Fujian Cosunter Pharmaceutical: The company and its subsidiaries received a total of 50.3444 million yuan in government subsidies and rewards.

BreakingsDec 10 18:45

Sinolink Securities: The favorable wind of medical policies arrives first, followed by innovation going abroad and performance reversal.

In 2025, sinolink believes that the core investment opportunities in the pharmaceutical sector will revolve around three main logics: 1) Innovation going overseas; 2) Demand recovery; 3) Policy expectation reversal.

Zhitong FinanceDec 9 07:31

Express News | Over 20 listed companies announced after hours that pharmaceuticals have been included in the new national medical insurance catalog, with multiple innovative drugs among them.

BreakingsNov 28 22:23

Fujian Cosunter Pharmaceutical (300436.SZ): The subsidiary's innovative drug Taizhongding for combating the COVID-19 virus has successfully been included in the national health insurance catalog.

On November 28, Gelonghui reported that fujian cosunter pharmaceutical (300436.SZ) announced the release of the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue (2024)" on November 28, 2024, which will take effect on January 1, 2025. The oral small molecule 3CL protease inhibitor innovative drug Atanavir tablets (project code: GST-HG171) / Ritonavir tablets combination packaging (trade name: Taizhongding) from fujian guangshenzhonglin biotechnology co., ltd., a subsidiary of fujian cosunter pharmaceutical specializing in innovative drugs, has been approved through national medical insurance negotiations for the first time.

Gelonghui FinanceNov 28 17:02